Trial Profile
An Open-label, Multicenter, Long-term Extension Study to Assess the Safety, Efficacy, and Pharmacodynamics of AT2101 in Adult Patients With Type 1 Gaucher Disease [EXTENSION OF 700244799]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2018
Price :
$35
*
At a glance
- Drugs Isofagomine tartrate (Primary)
- Indications Gaucher's disease type I
- Focus Adverse reactions
- Sponsors Amicus Therapeutics
- 21 May 2014 New trial record